Imatinib Completed Phase 2 Trials for Glioblastomas / Gliosarcoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00354913Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma